<DOC>
	<DOCNO>NCT00016224</DOCNO>
	<brief_summary>RATIONALE : Drugs thalidomide may stop growth cancer cell stop blood flow tumor . PURPOSE : Phase II trial study effectiveness thalidomide treat woman epithelial ovarian cancer respond previous therapy .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Refractory Resistant Epithelial Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine time progression disease patient platinum-refractory resistant ovarian epithelial carcinoma treat thalidomide . - Evaluate quality life patient treat regimen . OUTLINE : Patients receive oral thalidomide daily . Treatment continue absence disease progression unacceptable toxicity . Quality life assess baseline every 4 week . PROJECTED ACCRUAL : A total 45 patient accrue study within 9-15 month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial carcinoma Platinumrefractory resistant disease At least 1 prior nonplatinum chemotherapy agent require Prior bilateral salpingooophorectomy hysterectomy require Bidimensionally measurable disease OR CA125 great 100 units/mm3 PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 70100 % Life expectancy : More 3 month Hematopoietic : Not specify Hepatic : Bilirubin normal AST great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 50 mL/min Other : No prior malignancy except nonmelanoma skin cancer unless curatively treat evidence disease within past 5 year low risk recurrence No clinical circumstance would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No prior thalidomide Chemotherapy : See Disease Characteristics At least 4 week since prior cytotoxic therapy recover Endocrine therapy : At least 4 week since prior hormonal therapy recover Radiotherapy : At least 4 week since prior radiotherapy Surgery : See Disease Characteristics At least 4 week since prior major surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>